CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals (NASDAQ:CNSP) has reported its Q2 2025 financial results and provided updates on its drug development programs. The company maintains a strong cash position of $12.1 million, expected to sustain operations into H2 2026.
The company's lead program, TPI 287, an abeotaxane designed to cross the blood-brain barrier, showed promising results in Phase 1 trials for glioblastoma multiforme (GBM), achieving 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients when combined with bevacizumab. CNS plans to initiate a Phase 2 study in H1 2026 and engage with FDA on study design in 2025.
For Q2 2025, CNS reported a net loss of $2.4 million, slightly improved from $2.5 million in Q2 2024, with R&D expenses of $1.2 million and reduced G&A expenses of $1.2 million.
CNS Pharmaceuticals (NASDAQ:CNSP) ha comunicato i risultati finanziari del secondo trimestre 2025 e aggiornamenti sui programmi di sviluppo dei farmaci. La societ脿 dispone di una solida posizione di cassa di $12.1 milioni, sufficiente a sostenere le attivit脿 operative fino alla seconda met脿 del 2026.
Il programma principale, TPI 287, un abeotaxano progettato per attraversare la barriera emato-encefalica, ha mostrato risultati promettenti nella fase 1 per il glioblastoma multiforme (GBM): in 23 pazienti valutabili, la combinazione con bevacizumab ha prodotto 3 risposte complete e 9 risposte parziali. CNS prevede di avviare uno studio di Fase 2 nella prima met脿 del 2026 e di confrontarsi con la FDA sul disegno dello studio nel 2025.
Nel Q2 2025 CNS ha riportato una perdita netta di $2.4 milioni, lievemente migliorata rispetto ai $2.5 milioni del Q2 2024, con spese R&S pari a $1.2 milioni e spese generali e amministrative ridotte a $1.2 milioni.
CNS Pharmaceuticals (NASDAQ:CNSP) ha informado sus resultados financieros del segundo trimestre de 2025 y ha ofrecido actualizaciones sobre sus programas de desarrollo de f谩rmacos. La compa帽铆a mantiene una s贸lida posici贸n de efectivo de $12.1 millones, que se espera sostenga las operaciones hasta la segunda mitad de 2026.
El programa principal, TPI 287, un abeotaxano dise帽ado para cruzar la barrera hematoencef谩lica, mostr贸 resultados prometedores en la fase 1 para glioblastoma multiforme (GBM): en 23 pacientes evaluables, la combinaci贸n con bevacizumab logr贸 3 respuestas completas y 9 respuestas parciales. CNS planea iniciar un estudio de Fase 2 en la primera mitad de 2026 y entablar conversaciones con la FDA sobre el dise帽o del estudio en 2025.
En el Q2 2025, CNS report贸 una p茅rdida neta de $2.4 millones, ligeramente mejor que los $2.5 millones del Q2 2024, con gastos de I+D de $1.2 millones y gastos G&A reducidos a $1.2 millones.
CNS Pharmaceuticals (NASDAQ:CNSP)電� 2025雲� 2攵勱赴 鞁れ爜瓿� 鞎诫 臧滊皽 頂勲攴鸽灗鞐� 雽�頃� 鞐呺嵃鞚错姼毳� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� $12.1氚彪鞚� 順勱笀 氤挫湢毳� 鞙犾頃橁碃 鞛堨溂氅�, 鞚措姅 2026雲� 頃橂皹旮瓣箤歆� 鞖挫榿鞚� 歆�鞗愴暊 瓴冹溂搿� 鞓堨儊霅╇媹雼�.
欤检殧 頂勲攴鸽灗鞚� TPI 287鞚� 順堨暋雵岇灔氩届潉 韱店臣頃橂弰搿� 靹り硠霅� 鞎勲矤鞓ろ儊靷� 瓿勳棿 鞎诫搿�, 甑愲靹疙彫膦�(GBM) 雽�靸� 1靸侅棎靹� 鞙犽頃� 瓴瓣臣毳� 氤挫榾鞀惦媹雼�. 韽夑皜 雽�靸� 23氇� 欷� 氩犽皵鞁滌＜毵欔臣 氤戩毄頃� 鞕勳爠 甏�頃� 3瓯�, 攵�攵� 甏�頃� 9瓯�鞚� 雼劚頄堨姷雼堧嫟. CNS電� 2026雲� 靸侂皹旮办棎 2靸� 鞁滍棙鞚� 鞁滌瀾頃橁碃 2025雲勳棎 FDA鞕� 鞁滍棙 靹り硠鞐� 雽�頃� 雲检潣頃� 瓿勴殟鞛呺媹雼�.
2025雲� 2攵勱赴 CNS電� 靾滌啇鞁� $2.4氚彪鞚� 氤搓碃頄堨溂氅�, 鞚措姅 2024雲� 2攵勱赴鞚� $2.5氚彪鞐愳劀 靻岉彮 臧滌劆霅� 靾橃箻鞛呺媹雼�. 鞐瓣惮臧滊皽牍勲姅 $1.2氚彪, 韺愱磤牍勲姅 $1.2氚彪鞙茧 臧愳唽頄堨姷雼堧嫟.
CNS Pharmaceuticals (NASDAQ:CNSP) a annonc茅 ses r茅sultats financiers du deuxi猫me trimestre 2025 et fourni des mises 脿 jour sur ses programmes de d茅veloppement de m茅dicaments. La soci茅t茅 dispose d'une solide tr茅sorerie de 12,1 M$, suffisante selon elle pour assurer les op茅rations jusqu'脿 la seconde moiti茅 de 2026.
Le programme principal, TPI 287, un abeotaxane con莽u pour traverser la barri猫re h茅mato-enc茅phalique, a montr茅 des r茅sultats prometteurs en phase 1 pour le glioblastome multiforme (GBM) : sur 23 patients 茅valuables, la combinaison avec le bevacizumab a obtenu 3 r茅ponses compl猫tes et 9 r茅ponses partielles. CNS pr茅voit de lancer une 茅tude de phase 2 au premier semestre 2026 et de discuter du design de l'茅tude avec la FDA en 2025.
Pour le T2 2025, CNS a d茅clar茅 une perte nette de 2,4 M$, l茅g猫rement am茅lior茅e par rapport aux 2,5 M$ du T2 2024, avec des d茅penses R&D de 1,2 M$ et des frais G&A r茅duits 脿 1,2 M$.
CNS Pharmaceuticals (NASDAQ:CNSP) hat seine Finanzergebnisse f眉r das zweite Quartal 2025 ver枚ffentlicht und Updates zu seinen Wirkstoffentwicklungsprogrammen gegeben. Das Unternehmen verf眉gt 眉ber eine starke Barposition von $12.1 Millionen, die voraussichtlich den Betrieb bis in die zweite H盲lfte 2026 absichert.
Das f眉hrende Programm, TPI 287, ein Abeotaxan, das die Blut-Hirn-Schranke passieren soll, zeigte in Phase-1-Studien beim Glioblastom (GBM) vielversprechende Ergebnisse: Bei 23 auswertbaren Patienten f眉hrte die Kombination mit Bevacizumab zu 3 kompletten Remissionen und 9 partiellen Remissionen. CNS plant den Start einer Phase-2-Studie in H1 2026 und will 2025 mit der FDA zum Studiendesign sprechen.
F眉r Q2 2025 meldete CNS einen Nettoverlust von $2.4 Millionen, leicht verbessert gegen眉ber $2.5 Millionen im Q2 2024, mit F&E-Ausgaben von $1.2 Millionen und reduzierten Verwaltungs- und Gemeinkosten von $1.2 Millionen.
- Strong cash position of $12.1 million sufficient to fund operations into H2 2026
- Promising Phase 1 trial results for TPI 287 with 12 out of 23 patients showing complete or partial responses
- FDA Orphan Drug Designation granted for TPI 287 in multiple indications
- Reduced net loss compared to previous year ($2.4M vs $2.5M)
- Decreased G&A expenses from $1.4M to $1.2M year-over-year
- Increased R&D expenses from $1.1M to $1.2M year-over-year
- Phase 2 study not expected to commence until first half of 2026
- Continued operating losses with $2.4M net loss in Q2 2025
Insights
CNS Pharmaceuticals reports stable financial position with $12.1M cash runway while advancing TPI 287 for glioblastoma toward Phase 2 in 2026.
CNS Pharmaceuticals has reported Q2 2025 results showing a $12.1 million cash position that should fund operations into the second half of 2026. The company's quarterly net loss was $2.4 million, slightly improved from the $2.5 million loss in the same period of 2024. This financial stability provides a solid runway for their development programs.
The company's lead candidate, TPI 287, is positioned as a differentiated asset in the challenging glioblastoma multiforme (GBM) space. As an abeotaxane, TPI 287 shares the mechanism of action of established taxanes like paclitaxel, but critically, appears capable of crossing the blood-brain barrier - a significant hurdle in treating central nervous system malignancies. Early clinical signals are encouraging, with the Phase 1 combination trial with bevacizumab yielding 3 Complete Responses and 9 Partial Responses among 23 evaluable patients - a response rate of approximately
The company has already secured Orphan Drug Designation for TPI 287 across multiple indications (gliomas, pediatric neuroblastoma, and progressive supranuclear palsy), which provides development incentives including tax credits and potential market exclusivity. Management plans to engage with the FDA on a potential registrational study design for recurrent GBM in 2025, with the Phase 2 study expected to commence in the first half of 2026.
The slight increase in R&D expenses to
Strong cash position of
Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM)
HOUSTON, TX / / August 15, 2025 / ) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the second quarter ended June 30, 2025 and provided a corporate update.
"Every decision we make is grounded in our science and driven by a sense of urgency and responsibility to the patients and families counting on us for better outcomes. We are making excellent progress in our development strategy for TPI 287, working rapidly toward commencing a Phase 2 study for the treatment of GBM in the first half of 2026. Looking ahead, we are continuing to leverage our operational experience and global infrastructure to support TPI 287 while working to get our trial up and running and begin dosing patients with this exciting drug candidate," commented John Climaco, CEO of CNS Pharmaceuticals.
TPI 287: Late Stage, Novel Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel (Taxol庐) and docetaxel, in which it stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. While most taxanes are substrates for multi-drug resistant transporters, which maintain the blood brain barrier (BBB), TPI 287's clinical data suggest it has the potential to cross the BBB and treat CNS tumors. In a Phase 1 trial treating glioblastoma patients with TPI 287 in combination with bevacizumab (Avastin庐), the efficacy data included 3 Complete Responses and 9 Partial Responses out of 23 patients evaluable.
As previously announced, TPI 287 was granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.
CNS Pharmaceuticals plans to engage the FDA on the design of a study potentially focused on the registration of TPI 287 in recurrent GBM in 2025.
Summary of Financial Results for the Second Quarter 2025
The net loss for the three months ended June 30, 2025 was approximately
The Company reported research and development expenses of
General and administrative expense was approximately
As of June 30, 2025, the Company had cash of approximately
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.
For more information, please visit , and connect with the Company on , , and.
Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, the timing of the start of a trial of TPI 287and the Company's cash runway. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
SOURCE: CNS Pharmaceuticals, Inc.
View the original on ACCESS Newswire
FAQ
What were CNS Pharmaceuticals' (CNSP) Q2 2025 financial results?
What are the Phase 1 trial results for CNSP's TPI 287 in glioblastoma?
When will CNS Pharmaceuticals begin Phase 2 trials for TPI 287?
What regulatory designations has TPI 287 received from the FDA?
How long can CNS Pharmaceuticals fund its operations with current cash?
